Organon & Co [OGN] stock is trading at $18.07, down -3.78%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OGN shares have gain 5.30% over the last week, with a monthly amount drifted -1.04%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Organon & Co [NYSE: OGN] stock has seen the most recent analyst activity on September 06, 2024, when JP Morgan downgraded its rating to a Underweight and also boosted its price target to $20 from $18. Previously, Goldman downgraded its rating to Neutral on November 03, 2023, and dropped its price target to $16. On September 21, 2023, Barclays initiated with a Overweight rating and assigned a price target of $28 on the stock. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $33 on March 16, 2023. BofA Securities downgraded its rating to a Underperform and reduced its price target to $25 on October 14, 2022. Piper Sandler upgraded its rating to Overweight for this stock on September 06, 2022, and downed its price target to $34. In a note dated August 05, 2022, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $40 to $37.
Organon & Co [OGN] stock has fluctuated between $10.84 and $23.10 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Organon & Co [NYSE: OGN] shares were valued at $18.07 at the most recent close of the market. An investor can expect a potential return of 32.82% based on the average OGN price forecast.
Analyzing the OGN fundamentals
Organon & Co [NYSE:OGN] reported sales of 6.41B for the trailing twelve months, which represents a growth of 4.15%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 102.02, Equity is 42.48 and Total Capital is 150.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 17.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.77 points at the first support level, and at 17.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.66, and for the 2nd resistance point, it is at 19.24.
Ratios To Look Out For
For context, Organon & Co’s Current Ratio is 1.70. Further, the Quick Ratio stands at 1.21, while the Cash Ratio is 0.27. Considering the valuation of this stock, the price to sales ratio is 0.70, the price to book ratio is 9.44 and price to earnings (TTM) ratio is 3.58.
Transactions by insiders
Recent insider trading involved Weaver Kirke, Gen. Counsel & Corp. Secy., that happened on Feb 22 ’24 when 2720.0 shares were purchased.
